Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Robert B M LandeweLianne S GenslerDenis PoddubnyyProton RahmanMaja HojnikXiaoqi LiSoyi Liu LeageDavid AdamsHilde CarlierFilip E Van den Boschnull nullPublished in: Annals of the rheumatic diseases (2021)
Patients with axSpA who continued treatment with IXE were significantly less likely to flare and had significantly delayed time-to-flare compared with patients who withdrew to PBO.